Israel
· Delayed Price · Currency is ILS · Price in ILANovolog (Pharm-Up 1966) Statistics
Total Valuation
Novolog (Pharm-Up 1966) has a market cap or net worth of ILS 777.82 million. The enterprise value is 765.24 million.
| Market Cap | 777.82M |
| Enterprise Value | 765.24M |
Important Dates
The next estimated earnings date is Thursday, November 14, 2024.
| Earnings Date | Nov 14, 2024 |
| Ex-Dividend Date | Sep 3, 2024 |
Share Statistics
Novolog (Pharm-Up 1966) has 510.72 million shares outstanding. The number of shares has decreased by -0.61% in one year.
| Shares Outstanding | 510.72M |
| Shares Change (YoY) | -0.61% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 8.61% |
| Owned by Institutions (%) | 59.91% |
| Float | 330.36M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.46 |
| PB Ratio | 2.05 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 5.23, with an EV/FCF ratio of -62.31.
| EV / Earnings | -43.63 |
| EV / Sales | 0.45 |
| EV / EBITDA | 5.23 |
| EV / EBIT | 15.28 |
| EV / FCF | -62.31 |
Financial Position
The company has a current ratio of 0.96, with a Debt / Equity ratio of 52.39.
| Current Ratio | 0.96 |
| Quick Ratio | 0.86 |
| Debt / Equity | 52.39 |
| Debt / EBITDA | 1.37 |
| Debt / FCF | -16.84 |
| Interest Coverage | 3.32 |
Financial Efficiency
Return on equity (ROE) is -3.65% and return on invested capital (ROIC) is 5.43%.
| Return on Equity (ROE) | -3.65% |
| Return on Assets (ROA) | 1.20% |
| Return on Capital (ROIC) | 5.43% |
| Revenue Per Employee | 1.76M |
| Profits Per Employee | -18,366 |
| Employee Count | 955 |
| Asset Turnover | 0.59 |
| Inventory Turnover | 6.53 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -14.71% in the last 52 weeks. The beta is 0.40, so Novolog (Pharm-Up 1966)'s price volatility has been lower than the market average.
| Beta (5Y) | 0.40 |
| 52-Week Price Change | -14.71% |
| 50-Day Moving Average | 147.14 |
| 200-Day Moving Average | 147.68 |
| Relative Strength Index (RSI) | 50.63 |
| Average Volume (20 Days) | 278,848 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Novolog (Pharm-Up 1966) had revenue of ILS 1.68 billion and -17.54 million in losses. Loss per share was -0.04.
| Revenue | 1.68B |
| Gross Profit | 173.56M |
| Operating Income | 54.75M |
| Pretax Income | -3.51M |
| Net Income | -17.54M |
| EBITDA | 126.31M |
| EBIT | 54.75M |
| Loss Per Share | -0.04 |
Balance Sheet
The company has 234.51 million in cash and 206.82 million in debt, giving a net cash position of 27.69 million or 0.05 per share.
| Cash & Cash Equivalents | 234.51M |
| Total Debt | 206.82M |
| Net Cash | 27.69M |
| Net Cash Per Share | 0.05 |
| Equity (Book Value) | 394.73M |
| Book Value Per Share | 0.74 |
| Working Capital | -83.65M |
Cash Flow
In the last 12 months, operating cash flow was 48.58 million and capital expenditures -60.86 million, giving a free cash flow of -12.28 million.
| Operating Cash Flow | 48.58M |
| Capital Expenditures | -60.86M |
| Free Cash Flow | -12.28M |
| FCF Per Share | -0.02 |
Margins
Gross margin is 10.31%, with operating and profit margins of 3.25% and -1.04%.
| Gross Margin | 10.31% |
| Operating Margin | 3.25% |
| Pretax Margin | -0.21% |
| Profit Margin | -1.04% |
| EBITDA Margin | 7.50% |
| EBIT Margin | 3.25% |
| FCF Margin | -0.73% |
Dividends & Yields
This stock pays an annual dividend of 0.06, which amounts to a dividend yield of 3.86%.
| Dividend Per Share | 0.06 |
| Dividend Yield | 3.86% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.61% |
| Shareholder Yield | 4.46% |
| Earnings Yield | -2.30% |
| FCF Yield | -1.58% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |